ANI Q3 10-Q: $290.8M Revenue, $35.1M Net Income, $420.8M Cash, $676M Egetis Bridge
ANIP is trading near its 52-week low of $69.58 (7.8% above the low).
Summary
ANI's Q3 10-Q details $290.8M revenue, $35.1M net income and $420.8M cash, and discloses the $676M JPMorgan bridge facility backing its ~$560M cash offer for Egetis.
Key Events · Earnings and Guidance · ANIP
-
Q3 Revenue Up 27.6% to $290.8M
Net revenues of $290.777M versus $227.813M a year ago; operating income rose to $52.373M from $36.240M and net income to $35.149M, or $1.51 diluted EPS.
-
Cash Builds to $420.8M
Nine-month operating cash flow of $198.830M lifted cash and equivalents to $420.758M at September 30, 2026 from $285.585M at December 31, 2025.
-
$676M Bridge Funds Egetis Offer
A 364-day senior bridge facility of up to $676.0M with JPMorgan as administrative agent backs the ~$560M (SEK 5.6B) cash offer for Egetis at SEK 11.25 per share, a 27% premium to the 60-day VWAP.
-
Cortrophin Guidance Cut on Capacity
2026 Cortrophin Gel guidance was trimmed to $480-$500M from $520-$540M on specialty pharmacy capacity constraints, though Q3 Cortrophin revenue still grew 36.1% to $138.655M.
Analysis · ANIP · Life Sciences
The 10-Q fills in the numbers behind this morning's 8-K. Q3 revenue of $290.8M (+27.6% YoY) converted to $52.4M operating income and $35.1M net income ($1.51 diluted EPS), while nine-month operating cash flow reached $198.8M and lifted cash to $420.8M from $285.6M at year-end. That cash pile, plus a new $676M 364-day JPMorgan bridge facility, funds the ~$560M cash offer for Egetis (SEK 11.25/share, 27% premium to 60-day VWAP); the enterprise value nets to ~$434M after Egetis' $190M priority review voucher sale. The offset is the Cortrophin Gel guidance cut to $480-$500M on specialty pharmacy capacity constraints, even as total EBITDA and EPS guidance were raised. On the balance sheet sit $300.6M of Term Loan A and $316.3M of 2.25% converts due 2029, so the bridge is incremental leverage on top of existing debt.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANIP was trading at $75.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $69.58 to $95.57. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.